MichaelJamesBoyerMD

Pediatrics • Silverdale, WA

Physician

Join to view full profile

Are you Dr. Boyer?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 26 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
9951 Mickelberry Rd Nw
Kitsap Childrens Clinic Llp
Silverdale, WA 98383
Phone+1 360-692-9362

Fax+1 360-692-6214
Is this information wrong?

Summary

Dr. Michael Boyer, MD is a board certified pediatrician in Silverdale, Washington. He is currently licensed to practice medicine in Washington. He is affiliated with St. Michael Medical Center and Seattle Children's Hospital.

Education & Training

University of WashingtonFellowship, Child and Adolescent Psychiatry, 1976 - 1977
University of Washington School of MedicineClass of 1973

Certifications & Licensure

WA State Medical License 1975 - 2025
American Board of Pediatrics Pediatrics

Clinical Trials

Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer Start of enrollment: 2003 Nov 01
Completed
Phase 2

Publications & Presentations

PubMed

Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse.
Lomax AJ, Beith J, Bhadri V, Boyer M, Grimison P, Horvath LG, Kao S, Tattersall M, Thomas D, McNeil C> ;Intern Med J. 2016-12-01
P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial: Track: Advanced NSCLC.
Aix SP, Park K, Tan E, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Chih-Hsin Yang J, Märten A, Paz-Ares L> ;J Thorac Oncol. 2016-10-01
Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
Satgunaseelan L, Gupta R, Madore J, Chia N, Lum T, Palme CE, Boyer M, Scolyer RA, Clark JR> ;Pathology. 2016-10-01
Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Kao SC, Boyer MJ> ;J. Clin. Oncol.. 2016-09-20
EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors.
Barnet MB, O'Toole S, Horvath LG, Selinger C, Yu B, Ng CC, Boyer M, Cooper WA, Kao S> ;J Thorac Oncol. 2016-09-14
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L> ;Ann. Oncol.. 2016-07-01
140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell l...
Park K, Tan E, Zhang L, Hirsh V, O'Byrne K, Boyer M, Yang J, Mok T, Kim M, Paz-Ares L> ;J Thorac Oncol. 2016-04-01
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L> ;Ann. Oncol.. 2016-03-01
Salivary Duct Carcinoma: Clinicopathologic Features, Morphologic Spectrum, and Somatic Mutations
Michael Boyer, MD> ;Head & Neck. 2016-04-01
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials gro...
Davidson A, Veillard A, Tognela A, Chan MMK, Hughes BGM, Boyer M, Briscoe K, Begbie S, Abdi E, Crombie C, Long J, Boyce A, Lewis CR, Varma S, Broad A, Muljadi N, Chinc...> ;Ann. Oncol.. 2015-11-01
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA> ;Lung Cancer. 2015-08-01
Head and neck multidisciplinary team meetings: Effect on patient management.
Brunner M, Gore SM, Read RL, Alexander A, Mehta A, Elliot M, Milross C, Boyer M, Clark JR> ;Head Neck. 2015-07-01
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.
Mahon KL, Lin H, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Daly RJ, Henshall SM, ...> ;Br. J. Cancer. 2015-04-14
Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prosta...
Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes RJ, Chatfield MD, Boyer MJ, Stockler MR, Marx G, Gurney H, Mallesara G, Molloy PL, Horvath LG, Clark SJ> ;Br. J. Cancer. 2014-10-28
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
Lin H, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ, Horvath LG> ;Br. J. Cancer. 2014-05-13
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical T...
Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, ...> ;Eur. J. Cancer. 2014-03-01
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen M, Currow D, Schofield P, Nick Pavlakis BI, McLean J, Marsha...> ;J Thorac Dis. 2013-12-01
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai C, Boyer M, Su W, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazul...> ;J. Clin. Oncol.. 2013-09-20
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PLR, Pavlakis N, Boyer M, Stockler MR> ;Lung Cancer. 2013-09-01
Outcomes of chemoradiation for patients with locally advanced non-small-cell lung cancer.
Spina R, Chu SYY, Chatfield M, Chen J, Tin MM, Boyer M> ;Intern Med J. 2013-07-01
Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
Yip PY, Yu B, Cooper WA, Selinger CI, Ng CC, Kennedy CW, Kohonen-Corish MRJ, McCaughan BC, Trent RJ, Boyer MJ, Kench JG, Horvath LG, O'Toole SA> ;J Thorac Oncol. 2013-04-01
Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer.
McCaughan GJ, Blinman PL, Boyer MJ, Stockler MR> ;Intern Med J. 2013-04-01
The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol.
Dhillon HM, van der Ploeg HP, Bell ML, Boyer M, Clarke S, Vardy J> ;BMC Cancer. 2012-12-05
Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis...
Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FKF, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SCH, To KF, Tao Q, Ma BB, Chan AWH, Tong JHM, Erlichman...> ;J. Clin. Oncol.. 2012-09-20
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advance...
Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbel...> ;J. Clin. Oncol.. 2012-09-20
Join now to see all

Hospital Affiliations

St. Michael Medical CenterBremerton, Washington
Seattle Children's HospitalSeattle, Washington